Vesicular stomatitis virus: Re-inventing the bullet

Trends in Molecular Medicine

Volumn 10, Issue 5, 2004, Pages 210-216

  Lichty, Brian D ^a   Power, Anthony T ^a,b   Stojdl, David F ^a   Bell, John C ^a,b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG TARGETING; GENETIC ENGINEERING; IMMUNE RESPONSE; INFLUENZA; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; TARGET CELL; VESICULAR STOMATITIS VIRUS; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; CANCER VACCINES; DNA, VIRAL; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; INTERFERONS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VACCINES, DNA; VESICULAR STOMATITIS; VESICULOVIRUS; VIRAL MATRIX PROTEINS;

VESICULAR STOMATITIS VIRUS;

EID: 2342531185     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.03.003     Document Type: Review

References (48)

1. Mead D.G., et al. Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice. Science. 287:2000;485-487
2. Flanagan E.B., et al. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J. Virol. 75:2001;6107-6114
3. Stallknecht D.E. VSV-NJ on Ossabaw Island, Georgia. The truth is out there. Ann. New York Acad. Sci. 916:2000;431-436
4. Roberts A., et al. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:1999;3723-3732
5. Wagner R.R., Rose J.K. Rhabdoviridae: the viruses and their replication. Fields B.N., Knipe D.M. Fields Virology. 1996;1121-1136 Lippincott-Raven
6. Barr J.N., et al. Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus. Biochim. Biophys. Acta. 1577:2002;337-353
7. Clinton G.M., et al. The matrix (M) protein of vesicular stomatitis virus regulates transcription. Cell. 15:1978;1455-1462
8. Carroll A.R., Wagner R.R. Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J. Virol. 29:1979;134-142
9. Jayakar H.R., et al. Mutations in the PPPY motif of vesicular stomatitis virus matrix protein reduce virus budding by inhibiting a late step in virion release. J. Virol. 74:2000;9818-9827
10. Harty R.N., et al. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J. Virol. 75:2001;10623-10629
11. Martin-Serrano J., et al. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:2001;1313-1319
12. Black B.L., Lyles D.S. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J. Virol. 66:1992;4058-4064
13. von Kobbe C., et al. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol. Cell. 6:2000;1243-1252
14. Petersen J.M., et al. The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol. Cell. Biol. 20:2000;8590-8601
15. Petersen J.M., et al. Multiple vesiculoviral matrix proteins inhibit both nuclear export and import. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8590-8595
16. Stojdl D.F., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 4:2003;263-275
17. Enninga J., et al. Role of nucleoporin induction in releasing an mRNA nuclear export block. Science. 295:2002;1523-1525
18. Terstegen L., et al. The vesicular stomatitis virus matrix protein inhibits glycoprotein 130-dependent STAT activation. J. Immunol. 167:2001;5209-5216
19. Blondel D., et al. Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J. Virol. 64:1990;1716-1725
20. Kopecky S.A., et al. Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J. Virol. 75:2001;12169-12181
21. Kopecky S.A., Lyles D.S. Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J. Virol. 77:2003;4658-4669
22. Lawson N.D., et al. Recombinant vesicular stomatitis viruses from DNA. Proc. Natl. Acad. Sci. U. S. A. 92:1995;4477-4481
23. Schnell M.J., et al. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70:1996;2318-2323
24. Schnell M.J., et al. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11359-11365
25. Kretzschmar E., et al. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J. Virol. 71:1997;5982-5989
26. Haglund K., et al. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology. 268:2000;112-121
27. Roberts A., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J. Virol. 72:1998;4704-4711
28. Schlereth B., et al. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J. Virol. 74:2000;4652-4657
29. Rose N.F., et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol. 74:2000;10903-10910
30. Kahn J.S., et al. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology. 254:1999;81-91
31. Kahn J.S., et al. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J. Virol. 75:2001;11079-11087
32. Rose N.F., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell. 106:2001;539-549
33. Ezelle H.J., et al. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J. Virol. 76:2002;12325-12334
34. Grander D., Einhorn S. Interferon and malignant disease-how does it work and why doesn't it always? Acta Oncol. 37:1998;331-338
35. Stojdl D.F., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:2000;821-825
36. Fernandez M., et al. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76:2002;895-904
37. Balachandran S., Barber G.N. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life. 50:2000;135-138
38. Balachandran S., et al. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75:2001;3474-3479
39. Ebert O., et al. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res. 63:2003;3605-3611
40. Dummer R., et al. Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood. 97:2001;523-527
41. Porosnicu M., et al. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res. 63:2003;8366-8376
42. Bergman I., et al. Vesicular stomatitis virus expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2/neu overexpressing breast cancer cells. Virology. 316:2003;337-347
43. Schubert M., et al. Insertion of the human immunodeficiency virus CD4 receptor into the envelope of vesicular stomatitis virus particles. J. Virol. 66:1992;1579-1589
44. Schnell M.J., et al. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell. 90:1997;849-857
45. Obuchi M., et al. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77:2003;8843-8856
46. Francoeur A.M., et al. The isolation of interferon-inducing mutants of vesicular stomatitis virus with altered viral P function for the inhibition of total protein synthesis. Virology. 160:1987;236-245
47. Giedlin M.A., et al. Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology? Cancer Cell. 4:2003;241-243
48. Huang T.G., et al. Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice. Mol. Ther. 8:2003;434-440